NVCT
Nuvectis Pharma Inc
20.10$
-0.8%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -13.8% | +2.8% | -7.2% | -5.4% | +7.5% | +62.0% | -10.4% | +31.8% | -10.9% | -19.9% | -11.9% | |
| – | -13.8% | +2.8% | -7.2% | -5.4% | +7.5% | +62.0% | -10.4% | +31.8% | -10.9% | -19.9% | -11.9% | |
| – | -13.3% | +1.8% | -6.9% | -5.2% | +7.9% | +61.1% | -10.3% | +32.3% | -10.7% | -20.6% | -11.8% | |
| – | -13.3% | +1.8% | -6.9% | -5.2% | +7.9% | +61.1% | -10.3% | +32.3% | -10.7% | -20.6% | -11.8% | |
| – | +25.3% | -18.5% | +1.4% | +9.5% | +40.8% | +3.4% | +10.2% | +14.2% | +14.8% | -15.9% | +18.9% | |
| – | +25.3% | -18.5% | +1.4% | +9.5% | +40.8% | +3.4% | +10.2% | +14.2% | +14.8% | -15.9% | +18.9% | |
| – | -20.6% | -36.5% | +4.9% | +22.5% | +10.5% | +19.8% | +66.3% | +29.4% | -2.6% | -25.2% | +10.4% | |
| – | -26.9% | +14.9% | -10.7% | -12.3% | -11.6% | +115.7% | -19.5% | +42.3% | -23.3% | -22.8% | -36.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +8.2% | -4.9% | +2.1% | +2.0% | +13.1% | +2.3% | +7.2% | +6.3% | -4.0% | +7.3% | +0.3% |
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.